Exclusive Summary

• Elite Quality Endorsement: Holds top-tier US-FDA and UK-MHRA GMP certifications and is US-registered, enabling ready-to-launch distribution in the US and fast-track approvals in emerging markets (ASEAN, LATAM, MENA) via reliance pathways.
• Massive & Stable Long-Term Demand: Universal first-line endocrine therapy for postmenopausal HR+ breast cancer, targeting a massive patient base with an extended standard treatment duration of 5-10 years per patient, ensuring recurring revenue.
• High Margin & Competitive Pricing: Combines strict US/UK quality compliance with China’s highly efficient cost structure, empowering global distributors with sheer pricing advantages and lucrative profit margins to outcompete local generics.